Halfway Home Pets

Lets' get them the life they need

Oncotarget is an international peer-reviewed journal that delves mainly on cancer treatment, therapy areas, and the various treatment protocols used in enhancing the lives of cancer patients. Furthermore, the journal looks on the effects of the different cancer management programs and emerging treatments and how they influence the outcomes. In addition, the issues surrounding embracement of such therapies by both the patients and the healthcare providers are discussed.

RG Impact History

Research Gate uses data collected from the number of times articles published in a given journal are cited. In 2010, the RG Journal impact of Oncotarget was 0.19. In 2011, those figures increased to 1.69 meaning that every article published in this journal was cited at least 1.69 times. The figure rose to 2.90 in 2012 and reduced slightly in 2013 to 2.85. The best year for Oncotarget was 2004, when the average number of times any work published in the journal was cited hit 3.69 times. In the 2015/2016 period, the journal’s impact stood at 0.28 points lower than 2014.

Oncotarget to Start Publishing Issues Per Week

On September 19, 2017, Oncotarget reassured its readers about the availability of its scientific publications in places such as the PubMed Central, ISI/Web of Science, and Biological Abstracts among others. The company is working hard to ensure that it becomes the first research journal present a whole issue to PubMed within days after online publication.The journal works with prominent scientific indexes and archives to enhance the availability and accessibility of scientific findings to medical researchers and the general public. The company has now considered increasing the number of weekly issues to two to enhance the indexing process. In addition to oncology, the journal also publishes sub-sections touching on aging, immunology, and microbiology among others. So far, they have posted seven volumes since 2010 and are now publishing the eighth one. According to the journals Office of External and Legal Affairs, they are determined to face the challenges of the 21st century, and that’s why they are working around the clock to become known for making scientific findings rapidly available. As a journal by scientists for scientists, Oncotarget will act as a resource for scientists around the world in their effort to fight and end diseases.

Eric Lefkofsky has founded and co-founded several companies in his professional career. He founded his first company Inner Workings, in May 2001 and has gone on to six more since. His latest company, Tempus, Inc., is likely his most important one due to its work to battle cancer. Lefkofsky graduated from the University of Michigan in 1991 and earned his JD in 1994 from the University of Michigan Law School.

The company that Eric Lefkofsky co founded that he is perhaps best known for is Groupon, which he continues to serve as the Chairman of. Groupon is an e-commerce site that allows you to buy local products and experiences at a discount from participating vendors. Groupon has deals around the world and can provide people with products, vacations, and fun experiences at affordable prices.

Lefkofsky founded Tempus, Inc. in 2015. The company has built an operating system that doctors can use in order to deliver personalized cancer care to their patients. They have created the largest molecular and clinical data library in the world that doctors can easily access using this operating system. The operating system also uses machine learning in order to assist physicians with their diagnoses of tumors and how each is best treated. As Lefkofsky has stated, the operating system allows doctors to make real-time decisions in their care and the technology will help them to determine more effective treatment and results. Among the partners with Tempus are Penn Medicine, the Mayo Clinic, and Rush University Medical Center. To date, they have six partners and many more are expected in the short and long term.

Tempus, Inc. fits into Eric Lefkofsky’s philosophy of “Accelerated Disruption” which he wrote a book about in 2007. He shows convincingly in the book that someone that has a bright idea and offers better value, service, functionality, or convenience can disrupt an entire industry. However many fail to see how the ever-accelerating pace of technology means that challenge to their business can come from anywhere, be it an established player or a startup and completely upturn their business model. With Tempus, Lefkofsky hopes to disrupt cancer to everyone’s benefit.

To know more visit @: www.insidephilanthropy.com/guide-to-individual-donors/eric-lefkofsky.html

Eric Lefkofsky is the CEO as well as co-founder of Tempus. This is company dealing with technology. It has built an operating system that can help in the fight against cancer. Eric Lefkofsky is a founding partner of Lightbank which is a venture fund that invests in disruptive technologies.Eric Lefkofsky is the co-founder of Groupon and its Chairman too. This is a global e-commerce platform. He is the founder of Uptake Technologies which is an analytics platform for some of the largest industries in the world. He is also behind Mediaocean which provides various integrated procurement technologies. Echo Global Logistics is another transportation as well as logistics outsourcing company driven by technology that is promoted by Eric Lefkofsky. Next is InnerWorkings that is a provider of a number of print as well as promotional solutions globally.

Tempus is a cancer fighting startup. It comes from Eric Lefkofsky, the Groupon founder. With Tempus, Eric Lefkofsky wants to give data to doctors at the University of Chicago so that they can treat breast cancer patients in a much better way.Chicago-based Tempus has just announced its partnership with the University of Chicago Medicine Thursday. As per this partnership, Tempus will be providing molecular sequencing and analysis. This will be provided to the UChicago’s breast cancer specialists. It will help the doctors to create highly personalized treatment plans for their breast cancer patients. Here data will be analyzed from nearly 1,000 breast cancer patients. This type of data analysis will help doctors as well as researchers to uncover patterns that will be able to predict the response of patients to treatment.

Over time, it is expected that this data will help in providing better treatment along with highly improved patient outcomes.The fact is that breast cancer is one of the most common cancers today. But still there is very little accessible data that is available on the millions of patients who are battling or have battled this disease. Hence too many physicians are being forced to make treatment decisions with no help coming in from highly specific genetic information. Tempus will help them to make better informed decisions.